Boor Kathryn Jean 4

What Happened

• Kathryn Jean Boor, a director of Sarepta Therapeutics (SRPT), was granted 16,875 restricted stock units (RSUs) on 2026-06-04. The grant is reported as an award (transaction code A); no purchase price is applicable (N/A). RSUs represent the right to receive one share of common stock per RSU when they vest. The Form 4 was filed on 2026-06-05.

Key Details

• Transaction date: 2026-06-04 (reported on Form 4 filed 2026-06-05)
• Type/code: Award/Grant (A)
• Shares/units granted: 16,875 RSUs
• Price: N/A (RSU award, not an open-market trade)
• Vesting: RSUs vest on the earlier of the one-year anniversary of the grant and the next annual meeting of stockholders that is at least 50 weeks after the prior year’s meeting (per footnote)
• Shares owned after transaction: Not specified in the provided filing extract
• Filing timeliness: Filed the next day (appears timely; not marked late)

Context

• RSU grants are a form of compensation/retention for directors and do not represent an immediate market purchase or sale. The RSUs will convert to actual shares only upon meeting the vesting conditions; any future sale or withholding upon vesting would be reported separately.